KPV: The Calming Tail of a Hormone

The short version

KPV is one of the smallest peptides on this site — just three amino acids: lysine, proline, valine. It is the tail end (the last three residues) of a hormone called alpha-melanocyte-stimulating hormone, or alpha-MSH. The interesting thing is that this tiny tail keeps the parent hormone's anti-inflammatory power but leaves behind the pigment (skin-darkening) effect ^[22].

Unlike the other three peptides here, KPV is not really about building tissue — it is about calming the inflammation that can stop healing in its tracks. Most of its research is in animal models of inflamed gut ^[20]. Be clear-eyed about the stage of evidence: there are no published human clinical trials of KPV. It is sold for laboratory research only, it is not an approved drug or supplement, and this page lists no human dose.

What it is

KPV is the linear tripeptide L-lysyl-L-prolyl-L-valine (Lys-Pro-Val), corresponding to residues 11–13 — the C-terminal sequence — of alpha-MSH. Because it derives from a melanocortin hormone you will also see it written as alpha-MSH(11-13). Its defining feature in the literature is that it preserves anti-inflammatory activity without the pigmentary (melanogenic) action of the full hormone, making it distinct from tanning peptides ^[22]. It is a research peptide with no approved drug or supplement status in any jurisdiction.

How it works

KPV dampens inflammation primarily by suppressing two master inflammatory switches inside cells: the transcription factor NF-kB and the MAP-kinase signaling pathways. Quieting those reduces the output of pro-inflammatory messengers — cytokines such as IL-1beta and TNF-alpha ^[20].

There is an elegant delivery story in the gut. KPV is small enough to ride directly into intestinal lining cells on a di/tripeptide transporter called PepT1 (gene SLC15A1) — and PepT1 is upregulated precisely in inflamed intestinal tissue, so the transport route is most active exactly where the inflammation is ^[20]. At nanomolar concentrations, KPV taken up this way reduced NF-kB and MAP-kinase activation and cut cytokine secretion in both epithelial and immune cells ^[20]. Notably, its anti-inflammatory effect held in mice lacking the MC1R receptor, indicating an MC1R-independent route — it is not simply acting through the classic melanocortin receptor ^[21].

What the research shows

Mechanism in cells and mice. The foundational study showed PepT1-mediated KPV uptake into human intestinal epithelial cell lines and immune T cells, with nanomolar KPV inhibiting NF-kB and MAP-kinase signaling and reducing pro-inflammatory cytokine secretion; oral KPV reduced severity in two chemically induced mouse colitis models (DSS and TNBS) ^[20].

Colitis recovery. In a murine colitis study, the melanocortin-derived tripeptide produced earlier body-weight recovery, reduced colonic inflammatory infiltrate, and lower myeloperoxidase activity (a marker of inflammatory cell influx); the effect persisted in mice lacking MC1R, confirming an MC1R-independent mechanism ^[21].

Targeted delivery. Free KPV is fragile and digested quickly, so much recent research focuses on formulation. Hyaluronic-acid-functionalized nanoparticles carrying KPV, embedded in a chitosan/alginate hydrogel, delivered the peptide to inflamed colon tissue in mice and reduced colitis severity more than non-targeted formulations, downregulating TNF-alpha and accelerating mucosal healing ^[19]. A 2024 PepT1-targeted nanodrug co-assembling KPV with an immunosuppressant improved both acute and chronic colitis in mice, restoring tight-junction proteins and cutting inflammatory cytokines beyond either agent alone ^[18].

Breadth review. A comprehensive review of alpha-MSH and related tripeptides describes KPV and relatives as showing protective effects across fever, dermatitis, vasculitis, fibrosis, ocular, gut, brain, airway, arthritic, and organ-injury models; it explicitly delineates KPV as the anti-inflammatory option that lacks pigmentary action ^[22].

Reported effects, cautions and safety

The cautions for KPV are dominated by a single overwhelming fact — the evidence is entirely preclinical:

• No human trials. There are no published human clinical trials of KPV. The entire efficacy base is in vitro and animal (chiefly murine colitis), so human dosing, efficacy, and safety are all unestablished ^[20].
• Fragility and no human PK. Free KPV is a small, enzyme-labile tripeptide with no validated human pharmacokinetics. That is exactly why so much recent effort goes into nanoparticle formulations that keep it intact long enough to act ^[19].
• Marketing outruns evidence. Promotion of KPV for gut health, skin, or general anti-inflammatory uses runs well ahead of an evidence base that is mechanistic and preclinical, not clinical.
• Not a tanning peptide. Although KPV derives from alpha-MSH, it should be clearly distinguished from melanocortin agonists used for pigmentation. Its defining property is anti-inflammatory action without pigment effect ^[22].
• Citation hygiene. PMID and DOI errors are common in secondary web sources for KPV; identifiers should be verified at PubMed rather than copied from aggregator sites.
• Research-use status. KPV is sold for laboratory research only and is not an approved drug or dietary supplement in any major jurisdiction.

No community-anecdote reports are compiled in this desk's source material for KPV; all cautions above come from the cited literature.

Where it fits in recovery research

KPV is the useful outlier on this site. Where BPC-157, TB-500, and GHK-Cu all build, grow, or migrate tissue, KPV works the other side of repair — turning down the inflammatory noise that can prevent a wound from closing ^[20]. Its evidence is the most uniformly preclinical of the four (no human trials at all), but its mechanism is among the most precisely mapped: PepT1 transporter uptake and an MC1R-independent anti-inflammatory route ^[21]. It completes the group's four-sided picture of recovery: blood supply, cell movement, scaffolding, and inflammation control. See the comparison page for the side-by-side.